Athena Athena

X
[{"orgOrder":0,"company":"EXACT Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.9 million","upfrontCash":"Undisclosed","newsHeadline":"EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by EXACT Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The net proceeds from the private placement will be used for: completion of phase I study of ACT® in liver metastases, initiate planning and conduct supporting studies for multi-indication oncology basket trial, further development of ACT®-therapy ultrasound probe.

            Lead Product(s): ACT associated Chemotherapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $16.9 million Upfront Cash: Undisclosed

            Deal Type: Private Placement July 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY